These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 37000387)

  • 1. Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis.
    Fan H; Liu Z; Zhang P; Wu S; Han X; Huang Y; Zhu Y; Chen X; Zhang T
    Hepatol Int; 2023 Jun; 17(3):615-625. PubMed ID: 37000387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants.
    Chen S; Pang J; Huang R; Xue H; Chen X
    Hepatol Int; 2023 Jun; 17(3):595-605. PubMed ID: 36809487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, Is Amplified by the Integrated Effect of Fatty Liver Disease-Related Genetic Variants.
    Liu Z; Suo C; Shi O; Lin C; Zhao R; Yuan H; Jin L; Zhang T; Chen X
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):e855-e875. PubMed ID: 33387670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China.
    Liao S; An K; Liu Z; He H; An Z; Su Q; Li S
    J Clin Lab Anal; 2022 Sep; 36(9):e24626. PubMed ID: 35881683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.
    Petta S; Maida M; Grimaudo S; Pipitone RM; Macaluso FS; Cabibi D; Cammà C; Di Marco V; Sferrazza S; Craxì A
    Liver Int; 2016 Feb; 36(2):198-204. PubMed ID: 26259026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrepancies between Nonalcoholic and Metabolic-associated Fatty Liver Disease by Multiple Steatosis Assessment.
    Shao C; Ye J; Li X; Lin Y; Feng S; Liao B; Wang W; Gong X; Zhong B
    J Clin Transl Hepatol; 2022 Dec; 10(6):1013-1026. PubMed ID: 36381107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
    Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
    Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
    Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
    Younossi ZM; Paik JM; Al Shabeeb R; Golabi P; Younossi I; Henry L
    Hepatology; 2022 Nov; 76(5):1423-1437. PubMed ID: 35363908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between fatty liver index and controlled attenuation parameters as markers of metabolic dysfunction-associated fatty liver disease and bone mineral density: observational and two-sample Mendelian randomization studies.
    Zeng L; Li Y; Hong C; Wang J; Zhu H; Li Q; Cui H; Ma P; Li R; He J; Zhu H; Liu L; Xiao L
    Osteoporos Int; 2024 Apr; 35(4):679-689. PubMed ID: 38221591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive evaluation of NAFLD and the contribution of genes: an MRI-PDFF-based cross-sectional study.
    Yang A; Zhu X; Zhang L; Zhang Y; Zhang D; Jin M; Niu J; Zhang H; Ding Y; Lv G
    Hepatol Int; 2022 Oct; 16(5):1035-1051. PubMed ID: 35829866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
    Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
    J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.
    Dai YN; Xu CF; Pan HY; Huang HJ; Chen MJ; Li YM; Yu CH
    World J Clin Cases; 2022 May; 10(13):4097-4109. PubMed ID: 35665109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Additive Values of the Classification of Higher Serum Uric Acid Levels as a Diagnostic Criteria for Metabolic-Associated Fatty Liver Disease.
    He J; Ye J; Sun Y; Feng S; Chen Y; Zhong B
    Nutrients; 2022 Aug; 14(17):. PubMed ID: 36079844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-invasive Screening of Metabolic Associated Fatty Liver Disease and Affecting Factors in Primary Care.
    Balci IC; Haciagaoglu N; Oner C; Cetin H; Simsek EE
    J Coll Physicians Surg Pak; 2023 Apr; 33(4):390-395. PubMed ID: 37190709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores.
    Capela TL; Silva VM; Freitas M; Arieira C; Gonçalves TC; de Castro FD; Magalhães J; Cotter J
    BMC Gastroenterol; 2023 Dec; 23(1):437. PubMed ID: 38093213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C.
    Oliveira AIN; Malta FM; Zitelli PMY; Salles APM; Gomes-Gouvea MS; Nastri ACS; Pinho JRR; Carrilho FJ; Oliveira CP; Mendes-Corrêa MC; Pessoa MG; Mazo DF
    BMC Gastroenterol; 2021 Feb; 21(1):81. PubMed ID: 33622266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between Healthy Lifestyle and All-Cause Mortality in Individuals with Metabolic Associated Fatty Liver Disease.
    Wang X; Wang A; Zhang R; Cheng S; Pang Y
    Nutrients; 2022 Oct; 14(20):. PubMed ID: 36296904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.
    Nguyen VH; Le MH; Cheung RC; Nguyen MH
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2172-2181.e6. PubMed ID: 34033923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between serum 25-hydroxy vitamin D concentrations and mortality among individuals with metabolic dysfunction-associated fatty liver disease: a prospective cohort study.
    Zhang JJ; Yu HC; Li Y; Zhang YB; Geng TT; Lu Q; Liao YF; Guo KQ; Du L; Ruan HL; Yang K; Liu G; Pan A
    Am J Clin Nutr; 2022 Nov; 116(5):1409-1417. PubMed ID: 36107812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.